Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (GILD)
NASDAQ:GILD
GILD Analyst Ratings
Moderate Buy
15 Buy
6 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
GILD Stock 12 Month Forecast
Average Price Target
$119.33
▲(9.18%Upside)
| Highest Price Target$140.00 | Average Price Target$119.33 | Lowest Price Target$92.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$119
Buy
8.87%
Upside
Reiterated
05/22/25
Gilead Sciences scores well due to its strong financial performance and strategic focus on expanding its product pipeline. The company's efficient cash flow management and profitability provide a solid foundation, despite challenges like stagnant revenue growth and declining sales in certain segments. Technical indicators and valuation metrics further support its stability and fair market valuation, while the recent earnings call underscores promising growth in key areas.
Citi
$125
Buy
14.36%
Upside
Reiterated
06/11/25
Bank of America Securities
$126
Buy
15.28%
Upside
Reiterated
06/10/25
Goldman Sachs
$100
Hold
-8.51%
Downside
Reiterated
06/10/25
Morgan Stanley
$135
Buy
23.51%
Upside
Reiterated
06/10/25
Wells Fargo
$140
Buy
28.09%
Upside
Reiterated
06/10/25
RBC Capital
$92
Hold
-15.83%
Downside
Reiterated
06/10/25
Oppenheimer
$125
Buy
14.36%
Upside
Reiterated
06/10/25
Jefferies
$130
Buy
18.94%
Upside
Reiterated
06/04/25
Analysts Are Bullish on Top Healthcare Stocks: Icon (ICLR), Keros Therapeutics (KROS)We hosted mgmt to discuss the Len PrEP opportunity + pipeline ahead...co noted cont'd good dialog and on track for FDA approval (PDUFA 6/19) + lining up reimbursement over next 6-12m to support launch. Mgmt noted sig pot'l in swapping current pts (accretive to #s) + new pts not yet on PrEP - and investors catching on to even new 1x yearly LEN now starting Phase III (another bullish oppt'y). We predict likely on-time FDA approval and solid launch driving upside. Mgmt sounds positive on the lenacapavir PrEP launch -- with June 19th PDUFA just a few weeks out - co notes (1) things are moving according to plan and on track for a pot'l on time approval. (2) Co says they are launch ready w/ teams in place and on lining up reimbursement ~6mos for 75% access and 12 mos to reach 90%.
TD Cowen
$110
Buy
0.64%
Upside
Reiterated
06/02/25
Truist Financial
―
Hold
―
Reiterated
06/02/25
Leerink Partners
$115
Buy
5.22%
Upside
Reiterated
06/02/25
DBS
$125
Buy
14.36%
Upside
Reiterated
05/30/25
Needham
―
Hold
―
Reiterated
05/21/25
BMO Capital
$120
Buy
9.79%
Upside
Reiterated
05/15/25
Anito-cel Updates Maintain Competitive Edge - Potential 2026 Launch to Come
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$119
Buy
8.87%
Upside
Reiterated
05/22/25
Gilead Sciences scores well due to its strong financial performance and strategic focus on expanding its product pipeline. The company's efficient cash flow management and profitability provide a solid foundation, despite challenges like stagnant revenue growth and declining sales in certain segments. Technical indicators and valuation metrics further support its stability and fair market valuation, while the recent earnings call underscores promising growth in key areas.
Citi
$125
Buy
14.36%
Upside
Reiterated
06/11/25
Bank of America Securities
$126
Buy
15.28%
Upside
Reiterated
06/10/25
Goldman Sachs
$100
Hold
-8.51%
Downside
Reiterated
06/10/25
Morgan Stanley
$135
Buy
23.51%
Upside
Reiterated
06/10/25
Wells Fargo
$140
Buy
28.09%
Upside
Reiterated
06/10/25
RBC Capital
$92
Hold
-15.83%
Downside
Reiterated
06/10/25
Oppenheimer
$125
Buy
14.36%
Upside
Reiterated
06/10/25
Jefferies
$130
Buy
18.94%
Upside
Reiterated
06/04/25
Analysts Are Bullish on Top Healthcare Stocks: Icon (ICLR), Keros Therapeutics (KROS)We hosted mgmt to discuss the Len PrEP opportunity + pipeline ahead...co noted cont'd good dialog and on track for FDA approval (PDUFA 6/19) + lining up reimbursement over next 6-12m to support launch. Mgmt noted sig pot'l in swapping current pts (accretive to #s) + new pts not yet on PrEP - and investors catching on to even new 1x yearly LEN now starting Phase III (another bullish oppt'y). We predict likely on-time FDA approval and solid launch driving upside. Mgmt sounds positive on the lenacapavir PrEP launch -- with June 19th PDUFA just a few weeks out - co notes (1) things are moving according to plan and on track for a pot'l on time approval. (2) Co says they are launch ready w/ teams in place and on lining up reimbursement ~6mos for 75% access and 12 mos to reach 90%.
TD Cowen
$110
Buy
0.64%
Upside
Reiterated
06/02/25
Truist Financial
―
Hold
―
Reiterated
06/02/25
Leerink Partners
$115
Buy
5.22%
Upside
Reiterated
06/02/25
DBS
$125
Buy
14.36%
Upside
Reiterated
05/30/25
Needham
―
Hold
―
Reiterated
05/21/25
BMO Capital
$120
Buy
9.79%
Upside
Reiterated
05/15/25
Anito-cel Updates Maintain Competitive Edge - Potential 2026 Launch to Come
Best Analysts Covering Gilead Sciences
1 Month
xxx
Success Rate
20/30 ratings generated profit
Average Return
+2.90%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +2.90% per trade.
3 Months
xxx
Success Rate
21/30 ratings generated profit
Average Return
+3.43%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +3.43% per trade.
1 Year
Success Rate
13/16 ratings generated profit
Average Return
+21.54%
reiterated a buy rating 2 months ago
Copying Chris Schott's trades and holding each position for 1 Year would result in 81.25% of your transactions generating a profit, with an average return of +21.54% per trade.
2 Years
xxx
Success Rate
15/16 ratings generated profit
Average Return
+29.74%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 93.75% of your transactions generating a profit, with an average return of +29.74% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
GILD Analyst Recommendation Trends
Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
0
0
0
0
0
Buy
42
43
56
48
46
Hold
13
10
15
10
11
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
55
53
71
58
57
Each month's total comprises the sum of three months' worth of ratings.
GILD Financial Forecast
GILD Stock Forecast FAQ
What is GILD’s average 12-month price target, according to analysts?
Based on analyst ratings, Gilead Sciences’s 12-month average price target is 119.33.
What is GILD’s upside potential, based on the analysts’ average price target?
Gilead Sciences has 9.18% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GILD a Buy, Sell or Hold?
Gilead Sciences has a consensus rating of Moderate Buy which is based on 15 buy ratings, 6 hold ratings and 0 sell ratings.
What is Gilead Sciences’s price target?
The average price target for Gilead Sciences is 119.33. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $140.00 ,the lowest forecast is $92.00. The average price target represents 9.18% Increase from the current price of $109.3.
The highest analyst price target is $140.00 ,the lowest forecast is $92.00. The average price target represents 9.18% Increase from the current price of $109.3.
What do analysts say about Gilead Sciences?
Gilead Sciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.
How can I buy shares of GILD?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.